Validation of Anatomical and Biological Definition of Borderline Resectable Pancreatic Cancer According to the 2017 International Consensus for Survival in Patients Undergoing Upfront Surgery

Background: In 2017, international consensus have redefined patients with borderline resectable pancreatic ductal adenocarcinoma (BR-PDAC) according to three distinct dimensions: anatomical, biological, and conditional criteria. However, until now, there been few validation studies for this new The aim of study was validate the anatomical biological definitions BR-PDAC oncological outcomes in patient (R) undergoing upfront surgery. Methods: A total 404 who underwent surgery R BR PDAC from 2004 2020 were included. classified 2017 International Consensus Criteria; Resectable (n=259), Anatomical (BR-A) (n=43), Biologic (BR-B) (n=81), (BR-AB) (n=21). Results: BR-A (32.5%) BR-AB (33.4%) had higher postoperative complication rates than (16.5%) BR-B (27.2%) (P<0.001). R0 resection (65.1%) (61.9%) significantly lower those (85.7%) (80.2%) (P=0.003). comparison, (32.1%) (57.1%) early recurrence (within 6 months) (25.6%) 3-year recurrence-free survival (12.1%) (7.8%) (36.1%) (20.7%) Conclusion: Anatomically defined associated risk margin-positive resection, while biologically rates. These findings suggest that are useful predicting prognosis determining use neoadjuvant therapy.